Click on the test tubes to the left of any item below for more information.

16 July 2008. Microbiotix, Inc. receives an SBIR Phase I grant to discover and develop drugs that increase the efficacy of clinically relevant fluoroquinolones by specifically inhibiting induction of the SOS response.

26 May 2008. Microbiotix, Inc. receives an SBIR Phase I grant to support the research/development of specific inhibitors of fatty acid biosynthesis targets in P. aeruginosa for use as therapeutics.

28 January 2008. Microbiotix, Inc. receives an SBIR Phase I grant to develop novel antibiotics targeting the initiation of DNA synthesis in bacterial pathogens.

19 April 2007. Microbiotix receives an STTR Phase I grant to develop therapeutic agents that antagonize the pro-inflammatory signaling pathways resulting from the interaction between TLR5 and flagellins of P. aeruginosa and/or B. pseudomallei.